In recent years, remarkable advancements in the field of hepatology have revolutionized clinical practice and academic research. Innovations in therapeutic approaches and cutting-edge strategies in biomarker discovery have the potential to significantly improve outcomes for patients with chronic liver diseases and hepatocellular carcinoma.

This special issue aims to provide a platform for disseminating pioneering research and sharing novel insights in this rapidly evolving field. The journal welcomes submissions exploring the latest developments in pharmacological interventions, drug repurposing opportunities, and gene-based therapies designed to address the challenges posed by liver diseases. We also seek studies that shed light on diagnostic, predictive, and prognostic biomarkers, which aim to improve disease detection, monitoring, and personalized treatment approaches.

By bringing together the insights of researchers, clinicians, and industry experts, this special issue emphasizes the synergies between drug development and biomarker discovery, encouraging interdisciplinary collaborations that can accelerate the translation of groundbreaking scientific knowledge into practical clinical applications. Our goal is to showcase evidence-based approaches, methodologies, and technologies with the potential to transform the field of hepatology.

We cordially invite researchers, medical practitioners, and other interested parties to submit original research articles, comprehensive reviews, and thought-provoking perspectives that contribute to our understanding of innovative hepatology strategies. By working together, we can generate new ideas, encourage collaboration, and ultimately pave the way for more effective management of liver diseases. We look forward to receiving your valuable contributions, which will contribute to deepening our understanding of this dynamic field. In light of the growing global burden of liver-related pathologies, it is imperative that we collaborate to expedite novel therapeutic discoveries and optimize early detection methods.

Keywords: Chronic liver diseases, hepatocellular carcinoma, drug discovery, biomarker discovery, pharmacological interventions, diagnostic biomarkers, translational research, personalized medicine